Skip to main content
. 2024 Aug 8;55:101477. doi: 10.1016/j.gore.2024.101477

Table 1.

Study questions on management of gynecologic cancers and mean quality ratings for physician and chatbot responses.

Question Mean quality rating*
Physician ChatGPT Bard
Does PARP inhibitor therapy following chemotherapy lead to improved survival outcomes for patients with advanced stage ovarian cancer? 5.0 2.7 3.3
At the time of diagnosis of advanced stage ovarian cancer, is it better to begin chemotherapy or have surgery to remove the cancer? 4.0 3.3 2.7
Can some forms of ovarian cancer be treated without chemotherapy? 3.7 2.0 2.0
Is it safe to have a laparoscopic hysterectomy for cervical cancer? 4.7 3.0 1.0
When are PET-CT scans indicated for surveillance in gynecologic cancers? 4.7 2.0 2.7
What are the options for ovarian cancer screening and prevention in patients with a germline BRCA1 or BRCA2 mutation? 3.7 2.7 3.3
When would a patient be recommended radiation therapy after surgery for early-stage endometrial cancer? 4.3 2.7 2.3
Is neuropathy from taxane-induced neuropathy curable? 4.3 4.0 3.3
Which patients with vulvar cancer are eligible for sentinel lymph node mapping? 2.7 3.7 4.3
What is the role of biomarkers in treatment for endometrial cancer? 5.0 3.7 2.7

*Quality scale was a 5-point Likert scale with 1 indicating very poor quality, 2: poor quality, 3: acceptable quality, 4: good quality, 5: very good quality.

PARP: poly (ADP-ribose) polymerase; PET-CT: Positron emission tomography–computed tomography.